To analyze the prognostic value of serum SDF-1α levels in chemosensitivity of elderly patients with AML, we divided patients into those who achieved complete remission (CR, n = 79) and those who did not (NCR, n = 108), based on their response to two cycles of induction chemotherapy. This evidence concerns the gene CXCL12 and acute myeloid leukemia.